Skip to main content
Medrx Co.,Ltd. logo

Medrx Co.,Ltd. — Investor Relations & Filings

Ticker · 4586 ISIN · JP3921220004 T Manufacturing
Open in API
Filings indexed 79 across all filing types
Latest filing 2024-08-09 Interim / Quarterly Rep…
Country JP Japan
Listing T 4586

About Medrx Co.,Ltd.

https://www.medrx.co.jp/english/

Medrx Co., Ltd. is a pharmaceutical formulation development company that specializes in creating new dosage forms of medicines. The company's core focus is its transdermal absorption technology, which is used to develop innovative drug delivery systems like patches. These products are designed to improve patient health and quality of life (QOL) by providing alternatives for medications that are difficult to administer orally or by helping to prevent patients from forgetting to take their medicine. Medrx is actively engaged in research and development, managing a pipeline of pharmaceutical candidates that utilize its proprietary formulation technologies.

Recent filings

Filing Released Lang Actions
半期報告書－第23期(2024/01/01－2024/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) for Medrx Co., Ltd., covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial statements, management analysis (MDA), and business status updates, which are characteristic of an interim financial report. According to the filing definitions, this falls under the 'Interim / Quarterly Report' (IR) category. H1 2024
2024-08-09 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the '四国財務局長' (Shikoku Local Finance Bureau Chief). Section 1 explicitly states the reason for filing: the resolution by the Board of Directors on May 17, 2024, to issue stock acquisition rights (new share warrants) to directors, audit committee members, employees, and subsidiary directors, pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The core content details the terms of these stock acquisition rights, including issuance price, exercise price, exercise conditions (sales targets and market capitalization thresholds), and the allotment recipients. This structure and content strongly indicate a filing related to capital structure changes or financing activities, specifically the issuance of stock options/warrants. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details the terms of a new capital instrument issuance.
2024-05-17 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (596 characters) and contains a header section indicating it is a '確認書' (Confirmation Document) submitted to the Shikoku Local Finance Bureau Director, referencing Article 24-8, Paragraph 1 of the Financial Instruments and Exchange Act. The main body explicitly states that the Representative Director and CFO have confirmed the appropriateness of the '第23期第１四半期（自 2024年１月１日 至 2024年３月31日）の四半期報告書' (Quarterly Report for the 1st Quarter of the 23rd Period). This structure—a short confirmation document related to a quarterly report—is characteristic of a regulatory filing that confirms the accuracy of another primary report, rather than being the comprehensive report itself (which would be classified as IR). Since it is a specific regulatory confirmation document that doesn't fit perfectly into the main report categories (like IR or 10-K), and it is a formal submission, it falls best under the general 'Regulatory Filings' (RNS) category, as it is a required compliance document.
2024-05-10 Japanese
四半期報告書－第23期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Medrx Co., Ltd. in Japan. It contains detailed financial statements, management's discussion and analysis (MD&A), and information regarding share capital and stock options for the first quarter of the 23rd fiscal period (January 1, 2024, to March 31, 2024). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. Q1 2024
2024-05-10 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is a Japanese regulatory filing titled "臨時報告書" (Extraordinary Report) submitted to the Shikoku Local Finance Bureau. The content explicitly details the resolutions passed at the Annual General Meeting (AGM) held on March 28, 2024, including changes to the articles of incorporation (transitioning to a board with an audit committee), capital reduction, and the election/remuneration of directors and auditors. Since the document reports the official results of shareholder votes from a general meeting, it aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements'. The code for this is DVA.
2024-03-29 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (594 characters) and contains a header section identifying it as a '確認書' (Confirmation Document) submitted to the Shikoku Local Finance Bureau Director, referencing Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. The main body confirms that the President and CFO have verified the appropriateness of the contents of the company's 22nd period (FY ended Dec 31, 2023) '有価証券報告書' (Annual Securities Report, equivalent to a 10-K). Since this document is a confirmation *about* the Annual Securities Report, and not the report itself, and it is a specific regulatory confirmation filing, it does not fit perfectly into the main report categories (10-K, IR). Given its nature as a formal regulatory confirmation related to statutory filings, and its brevity suggesting it's an announcement or certification rather than the full report, it most closely aligns with a general Regulatory Filing (RNS) or potentially a specific certification document. However, since it is a formal certification required by law regarding the accuracy of a major filing (like a 10-K), and there isn't a specific code for 'Certification of Accuracy of Annual Report', RNS serves as the best general regulatory fallback for non-standard, mandatory filings that aren't the primary report. FY 2023
2024-03-29 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.